eLife (Mar 2019)
Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma
- Jianing Xu,
- Ed Reznik,
- Ho-Joon Lee,
- Gunes Gundem,
- Philip Jonsson,
- Judy Sarungbam,
- Anna Bialik,
- Francisco Sanchez-Vega,
- Chad J Creighton,
- Jake Hoekstra,
- Li Zhang,
- Peter Sajjakulnukit,
- Daniel Kremer,
- Zachary Tolstyka,
- Jozefina Casuscelli,
- Steve Stirdivant,
- Jie Tang,
- Nikolaus Schultz,
- Paul Jeng,
- Yiyu Dong,
- Wenjing Su,
- Emily H Cheng,
- Paul Russo,
- Jonathan A Coleman,
- Elli Papaemmanuil,
- Ying-Bei Chen,
- Victor E Reuter,
- Chris Sander,
- Scott R Kennedy,
- James J Hsieh,
- Costas A Lyssiotis,
- Satish K Tickoo,
- A Ari Hakimi
Affiliations
- Jianing Xu
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States
- Ed Reznik
- ORCiD
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, United States; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, United States
- Ho-Joon Lee
- Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, United States; Rogel Cancer Center, University of Michigan, Ann Arbor, United States
- Gunes Gundem
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, United States; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, United States
- Philip Jonsson
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, United States
- Judy Sarungbam
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States
- Anna Bialik
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States
- Francisco Sanchez-Vega
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, United States
- Chad J Creighton
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, United States; Department of Medicine, Baylor College of Medicine, Houston, United States
- Jake Hoekstra
- Department of Pathology, University of Washington, Seattle, United States
- Li Zhang
- Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, United States
- Peter Sajjakulnukit
- Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, United States
- Daniel Kremer
- Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, United States; Graduate Program in Chemical Biology, University of Michigan, Ann Arbor, United States
- Zachary Tolstyka
- Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, United States
- Jozefina Casuscelli
- Department of Urology, Ludwig-Maximilians University, Munich, Germany
- Steve Stirdivant
- Metabolon Inc, Durham, United States
- Jie Tang
- Genomics Core, Cedars-Sinai Medical Center, Los Angeles, United States
- Nikolaus Schultz
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, United States; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, United States
- Paul Jeng
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States
- Yiyu Dong
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States
- Wenjing Su
- Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, United States
- Emily H Cheng
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States
- Paul Russo
- Department of Urology, Memorial Sloan Kettering Cancer Center, New York, United States
- Jonathan A Coleman
- Department of Urology, Memorial Sloan Kettering Cancer Center, New York, United States
- Elli Papaemmanuil
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, United States; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, United States
- Ying-Bei Chen
- ORCiD
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States
- Victor E Reuter
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States
- Chris Sander
- cBio Center, Dana-Farber Cancer Institute, Boston, United States; Department of Cell Biology, Harvard Medical School, Boston, United States
- Scott R Kennedy
- Department of Pathology, University of Washington, Seattle, United States
- James J Hsieh
- Department of Medicine, Molecular Oncology, Siteman Cancer Center, Washington University, St. Louis, United States
- Costas A Lyssiotis
- Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, United States; Department of Internal Medicine, Division of Gastroenterology, Rogel Cancer Center, University of Michigan, Ann Arbor, United States
- Satish K Tickoo
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States
- A Ari Hakimi
- ORCiD
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States
- DOI
- https://doi.org/10.7554/eLife.38986
- Journal volume & issue
-
Vol. 8
Abstract
While genomic sequencing routinely identifies oncogenic alterations for the majority of cancers, many tumors harbor no discernable driver lesion. Here, we describe the exceptional molecular phenotype of a genomically quiet kidney tumor, clear cell papillary renal cell carcinoma (CCPAP). In spite of a largely wild-type nuclear genome, CCPAP tumors exhibit severe depletion of mitochondrial DNA (mtDNA) and RNA and high levels of oxidative stress, reflecting a shift away from respiratory metabolism. Moreover, CCPAP tumors exhibit a distinct metabolic phenotype uniquely characterized by accumulation of the sugar alcohol sorbitol. Immunohistochemical staining of primary CCPAP tumor specimens recapitulates both the depletion of mtDNA-encoded proteins and a lipid-depleted metabolic phenotype, suggesting that the cytoplasmic clarity in CCPAP is primarily related to the presence of glycogen. These results argue for non-genetic profiling as a tool for the study of cancers of unknown driver.
Keywords